A 12-month randomized crossover study on the effects of Lanreotide Autogel and Octreotide long-acting repeatable on GH and IGF-l in patients with acromegaly

Clinical Endocrinology

Volumn 68, Issue 3, 2008, Pages 473-480

  Andries, Magdalene ^a   Glintborg, Dorte ^a   Kvistborg, Annette ^a   Hagen, Claus ^a   Andersen, Marianne ^a  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPEPTIN; GROWTH HORMONE; OCTREOTIDE; PEGVISOMANT; SOMATOMEDIN C;

ABDOMINAL CRAMP; ABDOMINAL PAIN; ACROMEGALY; ACUTE CHOLECYSTITIS; ADULT; AGED; AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; CHEMICAL ANALYSIS; CHOLELITHIASIS; CLINICAL ARTICLE; CLINICAL EVALUATION; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIARRHEA; DRUG DOSE TITRATION; DRUG EFFECT; FATIGUE; FEMALE; HEADACHE; HUMAN; INJECTION SITE NODULE; MALE; METHODOLOGY; MYALGIA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; THERAPY EFFECT; TREATMENT FAILURE;

ACROMEGALY; ADULT; AGED; CROSS-OVER STUDIES; FEMALE; HUMAN GROWTH HORMONE; HUMANS; INSULIN-LIKE GROWTH FACTOR I; MALE; MIDDLE AGED; OCTREOTIDE; PEPTIDES, CYCLIC; SOMATOSTATIN; YOUNG ADULT;

EID: 39149133993     PISSN: 03000664     EISSN: 13652265     Source Type: Journal    
DOI: 10.1111/j.1365-2265.2007.03067.x     Document Type: Article

References (25)

1. Giustina, A., Barkan, A., Casanueva, F.F., Cavagnini, F., Frohman, L., Ho, K., Veldhuis, J., Wass, J., von Werder, K. Melmed, S. (2000) Criteria for cure of acromegaly: a consensus statement. Journal of Clinical Endocrinology and Metabolism, 85, 526 529.
2. Ayuk, J., Clayton, R.N., Holder, G., Sheppard, M.C., Stewart, P.M. Bates, A.S. (2004) Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 1613 1617.
3. Biermasz, N.R., Dekker, F.W., Pereira, A.M., van Thiel, S.W., Schutte, P.J., van, D.H., Romijn, J.A. Roelfsema, F. (2004) Determinants of survival in treated acromegaly in a single center: predictive value of serial insulin-like growth factor I measurements. Journal of Clinical Endocrinology and Metabolism, 89, 2789 2796.
4. Holdaway, I.M., Rajasoorya, R.C. Gamble, G.D. (2004) Factors influencing mortality in acromegaly. Journal of Clinical Endocrinology and Metabolism, 89, 667 674.
5. Orme, S.M., McNally, R.J., Cartwright, R.A. Belchetz, P.E. (1998) Mortality and cancer incidence in acromegaly: a retrospective cohort study. United Kingdom Acromegaly Study Group. Journal of Clinical Endocrinology and Metabolism, 83, 2730 2734.
6. Ludecke, D.K. Abe, T. (2006) Transsphenoidal microsurgery for newly diagnosed acromegaly: a personal view after more than 1000 operations. Neuroendocrinology, 83, 230 239.
7. Heron, I., Thomas, F., Dero, M., Gancel, A., Ruiz, J.M., Schatz, B. Kuhn, J.M. (1993) Pharmacokinetics and efficacy of a long-acting formulation of the new somatostatin analog BIM 23014 in patients with acromegaly. Journal of Clinical Endocrinology and Metabolism, 76, 721 727.
8. Lancranjan, I., Bruns, C., Grass, P., Jaquet, P., Jervell, J., Kendall-Taylor, P., Lamberts, S.W., Marbach, P., Orskov, H., Pagani, G., Sheppard, M. Simionescu, L. (1996) Sandostatin LAR: a promising therapeutic tool in the management of acromegalic patients. Metabolism, 45, 67 71.
9. Cozzi, R., Dallabonzana, D., Attanasio, R., Barausse, M. Oppizzi, G. (1999) A comparison between octreotide-LAR and lanreotide-SR in the chronic treatment of acromegaly. European Journal of Endocrinology, 141, 267 271.
10. Turner, H.E., Vadivale, A., Keenan, J. Wass, J.A. (1999) A comparison of lanreotide and octreotide LAR for treatment of acromegaly. Clinical Endocrinology, 51, 275 280.
11. Freda, P.U., Katznelson, L., van der Lely, A.J., Reyes, C.M., Zhao, S. Rabinowitz, D. (2005) Long-acting somatostatin analog therapy of acromegaly: a meta-analysis. Journal of Clinical Endocrinology and Metabolism, 90, 4465 4473.
12. Flogstad, A.K., Halse, J., Haldorsen, T., Lancranjan, I., Marbach, P., Bruns, C. Jervell, J. (1995) Sandostatin LAR in acromegalic patients: a dose-range study. Journal of Clinical Endocrinology and Metabolism, 80, 3601 3607.
13. Alexopoulou, O., Abrams, P., Verhelst, J., Poppe, K., Velkeniers, B., Abstract, R. Maiter, D. (2004) Efficacy and tolerability of lanreotide Autogel therapy in acromegalic patients previously treated with octreotide LAR. European Journal of Endocrinology, 151, 317 324.
14. Antonijoan, R.M., Barbanoj, M.J., Cordero, J.A., Peraire, C., Obach, R., Valles, J., Cherif-Cheikh, R., Torres, M.L., Bismuth, F. Montes, M. (2004) Pharmacokinetics of a new Autogel formulation of the somatostatin analogue lanreotide after a single subcutaneous dose in healthy volunteers. Journal of Pharmacy and Pharmacology, 56, 471 476.
15. Caron, P., Beckers, A., Cullen, D.R., Goth, M.I., Gutt, B., Laurberg, P., Pico, A.M., Valimaki, M. Zgliczynski, W. (2002) Efficacy of the new long-acting formulation of lanreotide (lanreotide Autogel) in the management of acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 99 104.
16. Caron, P., Bex, M., Cullen, D.R., Feldt-Rasmussen, U., Pico Alfonso, A.M., Pynka, S., Racz, K., Schopohl, J., Tabarin, A. Valimaki, M.J. (2004) One-year follow-up of patients with acromegaly treated with fixed or titrated doses of lanreotide Autogel. Clinical Endocrinology, 60, 734 740.
17. Caron, P., Cogne, M., Raingeard, I., Bex-Bachellerie, V. Kuhn, J.M. (2006) Effectiveness and tolerability of 3-year lanreotide Autogel treatment in patients with acromegaly. Clinical Endocrinology, 64, 209 214.
18. Ashwell, S.G., Bevan, J.S., Edwards, O.M., Harris, M.M., Holmes, C., Middleton, M.A. James, R.A. (2004) The efficacy and safety of lanreotide Autogel in patients with acromegaly previously treated with octreotide LAR. European Journal of Endocrinology, 150, 473 480.
19. van Thiel, S.W., Romijn, J.A., Biermasz, N.R., Ballieux, B.E., Frolich, M., Smit, J.W., Corssmit, E.P., Roelfsema, F. Pereira, A.M. (2004) Octreotide long-acting repeatable and lanreotide Autogel are equally effective in controlling growth hormone secretion in acromegalic patients. European Journal of Endocrinology, 150, 489 495.
20. Flogstad, A.K., Halse, J., Bakke, S., Lancranjan, I., Marbach, P., Bruns, C. Jervell, J. (1997) Sandostatin LAR in acromegalic patients: long-term treatment. Journal of Clinical Endocrinology and Metabolism, 82, 23 28.
21. Altman, D.G. (1991) Practical Statistics for Medical Research. Chapman & Hall/CRC.
22. Chanson, P. (2004) Efficacy and safety of lanreotide Autogel in the treatment of acromegaly: a phase III multicenter open trail. Poster ECE, Lisbon (P1-373). 1-9-2004.
23. Cozzi, R., Attanasio, R., Montini, M., Pagani, G., Lasio, G., Lodrini, S., Barausse, M., Albizzi, M., Dallabonzana, D. Pedroncelli, A.M. (2003) Four-year treatment with octreotide-long-acting repeatable in 110 acromegalic patients: predictive value of short-term results? Journal of Clinical Endocrinology and Metabolism, 88, 3090 3098.
24. Freda, P.U. (2002) Somatostatin analogs in acromegaly. Journal of Clinical Endocrinology and Metabolism, 87, 3013 3018.
25. Ipsen (2005) Lanreotide and Liver Function (Safety Response). CDP Report and Epidemiology, Brøndby, Denmark.